Drug Profile


Alternative Names: SKL-11197; SKL-NP

Latest Information Update: 20 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK biopharmaceuticals; SK Life Science
  • Developer SK Life Science
  • Class Analgesics
  • Mechanism of Action 12-lipoxygenase inhibitors; 15-lipoxygenase inhibitors; Calcium channel modulators; Hyperpolarisation-activated cation channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 30 Jun 2015 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
  • 01 Jun 2013 SK Life Science completes a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)
  • 19 Feb 2013 SK Life Science completes enrolment in a phase II trial in Neuropathic pain (diabetic peripheral neuropathy) in USA (NCT01521598)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top